Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma
Public ClinicalTrials.gov record NCT03600441. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study in patients with relapsed/refractory follicular lymphoma who have undergone at least 3 lines of therapy. Patients will receive abexinostat 80 mg (4 × 20 mg tablets) twice a day (BID) in a "one week on, one week off" schedule.
Study identification
- NCT ID
- NCT03600441
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 139 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 26, 2018
- Primary completion
- Dec 30, 2027
- Completion
- Dec 30, 2029
- Last update posted
- Apr 9, 2025
2018 – 2029
United States locations
- U.S. sites
- 9
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Advocate Medical Group - Park Ridge, Luther Lane - Oncology | Park Ridge | Illinois | 60068 | — |
| Norton Cancer Institute - St. Matthews Campus | Louisville | Kentucky | 40207 | — |
| Clinical Research Alliance Inc | Lake Success | New York | 11042 | — |
| Manhattan Hematology Oncology Center | New York | New York | 10016 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Bone Marrow Transplant Hematology Oncology Associates | Pittsburgh | Pennsylvania | 15224-2156 | — |
| Arlington Cancer Center | Arlington | Texas | 76012 | — |
| Central Texas Veterans Health Care System - NAVREF | Temple | Texas | 76504 | — |
| Vista Oncology Inc. PS | Olympia | Washington | 98506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03600441, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 9, 2025 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03600441 live on ClinicalTrials.gov.